Review


DOI :10.5222/j.child.2013.001   IUP :10.5222/j.child.2013.001    Full Text (PDF)

Invasive Meningococcal Disease and Vaccines

Selda Hançerli TörünNuran Salman

Abstract Meningococcal diseases continue to have a major public health impact in many countries. Fatality rate of invasive meningococcal disease (IMD) in pediatric patients is 10 %. At least 75 % of cases of are caused byserogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immunization. Plain polysaccharides vaccines for Neisseria meningit have been in use for approximately 20 years, both to prevent invasive disease in high-risk population and to control disease outbreaks. The preferred vaccine for people ages 2-55 years is Meningococcal conjugate vaccine (MCV4).

DOI :10.5222/j.child.2013.001   IUP :10.5222/j.child.2013.001    Full Text (PDF)

İnvaziv Menengokok Hastalığı ve Aşıları

Selda Hançerli TörünNuran Salman

Meningokok infeksiyonları bütün dünyada önemli sağlık sorunları arasında yer almaya devam etmektedir. İnvaziv Meningokok hastalığı çocukluk çağında % 10 oranında ölümcül olabilmektedir. Vakaların % 75’inden serogrup A, C, Y ve W135 sorumludur. İMH aşılama ile önlenebilir bir hastalıktır. İnfeksiyonların önlenmesi için uzun yıllardan beri iki yaşından itibaren uygulanan polisakkarid aşılar risk gruplarında ve salgın kontrolünde kullanılmaktadır. İki-55 yaş arasında tercih edilen aşı, meningokok konjuge aşıdır (MCV4).


PDF View

References

  • 1. Centers for Disease Prevention and Control. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-7):1-10. google scholar
  • 2. Bilukha OO, Rosenstein N. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;54(RR-7):1-21. PMid:15917737. google scholar
  • 3. Anderson MS, Glode MP, Smith AL. Meningococcal disease, “Feigin RP, Cherr JD, Demmler GJ, Kaplan SL (eds): Texbook of Pediatric Infectious Diseases 5. baskı” kitabında s.1265-1280, Saunders, Philadelphia 2004. google scholar
  • 4. Boulton RB, Alder SC, Mottice S, Catinella AP, Byington CL. Invasive meningococcal disease, Utah, 1995-2005, Emer Infect Dis 2007;13(8). google scholar
  • 5. Brouwer MC, Read RC, Van de Beek D. Host genetics and out come in meningococcal disease: a systematic review and meta-analysis, Lancet Infect Dis 2010;10:262-74 http://dx.doi.org/10.1016/S1473-3099(10)70045-1. google scholar
  • 6. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose range study assessing immunogenity and safety of one dose of a new candidate meningococcal serogroups A C, W-135, Y, tctanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of the life and in young children Vaccine 2010;28-744. google scholar
  • 7. Ceyhan M, Yıldırım İ, Balmer P, et al. A Prospective study of etiology of childhold acute bacterial meningitis, Turkey, Emer Infect Dis 2008;14:1089-96. http://dx.doi.org/10.3201/eid1407.070938 PMid:18598630 PMCid:2600347. google scholar
  • 8. Doğancı L, Baysallar M, Saraçlı MA, Hasçelik G, Pahsa A. Neisseria meningitidis W135 Turkey, Emerg Infect Dis 2004;10-936. google scholar
  • 9. Badur S, Bakır M. Aşı kitabı. Akademi Yayınevi, Meningokok aşıları, 245-53. google scholar
  • 10. Stephens DS, Greanwood B, Brandtzaeg P. Epidemic meningitidis, meningococcaemia and Neisseria meningitidis, Lancet 2007;369:2196. http://dx.doi.org/10.1016/S0140-6736(07)61016-2. google scholar
  • 11. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9:285-98. http://dx.doi.org/10.1586/erv.10.3 PMid:20218857. google scholar
  • 12. Goria MC, Paiva MV, Salqueiro VC et al. Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008, Enterm Infect Microbiol Clin 2011;29:85-9. http://dx.doi.org/10.1016/j.eimc.2010.07.016 PMid:21345528. google scholar
  • 13. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002;51(RR-2):1-35. google scholar
  • 14. DEPARTMENT OF HEALTH & HUMAN SERVICES FDA/ CBER/OVRR/DVRPAhttp://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM246961.pdf. google scholar
  • 15. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80. PMid:411104. google scholar
  • 16. Roberts J, Bryett K. Incidence of reactions to meningococcal A and C vaccine among U.K. schoolchildren. Public Health 1988;102:471-6. http://dx.doi.org/10.1016/S0033-3506(88)80085-4 google scholar
  • 17. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines, Vaccine 2009;27(Suppl 2):B30-41. http://dx.doi.org/10.1016/j.vaccine.2009.05.003 PMid:19477560. google scholar
  • 18. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the 57 Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 2005;54(RR-7):1-21. PMid:15917737. google scholar
  • 19. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines, Vaccine 2009;27(Suppl 2):B30-41. http://dx.doi.org/10.1016/j.vaccine.2009.05.003 PMid:19477560. google scholar
  • 20. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Morb Mortal Wkly Rep 2010;59(9):273. PMid:20224545. google scholar
  • 21. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011, MMWR Morb Mortal Wkly Rep 2011;60(30): 1018-9. PMid:21814165. google scholar
  • 22. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents, Clin Infect Dis 2009;49(1):e110.http://dx.doi.org/10.1086/599117 PMid:19476428 google scholar
  • 23. Vesikari T, Karvonen A, Lindbland N, et al. Immunogenicity of one dose of an investigational eningococcal tetravalent tetanus-toxoid conjugate (MenACWY-TT) vaccine in toddlers and children after one year, 6th Annual Meeting of the World Society for Pediatric Infectious Diseases-WSPID, (Abstract 582) Buenos Aires, Argentina, 18-22 November (2009). google scholar
  • 24. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years, Vaccine 2009;27(1):161-8. http://dx.doi.org/10.1016/j.vaccine.2008.08. PMid:18834910. google scholar
  • 25. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27 Suppl2:B51-http://dx.doi.org/10.1016/j.vaccine.2009.04.063 PMid:19477562. google scholar
  • 26. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304 http://dx.doi.org/10.1056/NEJMoa1003812 PMid:21675889. google scholar
  • 27. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Morb Mortal Wkly Rep 2011;60(3):72 PMid:21270745. google scholar
  • 28. Dinleyici EC, Ceyhan M. The dynamic and changing epidemiology of meningococcal disease at the country-based level: The experience in Turkey, Expert Rev Vaccines 2012 (in press). http://dx.doi.org/10.1586/erv.12.29 PMid:22827237 google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Hançerli Törün, S., & Salman, N. (2013). Invasive Meningococcal Disease and Vaccines. Journal of Child, 13(1), 1-5. https://doi.org/10.5222/j.child.2013.001


AMA

Hançerli Törün S, Salman N. Invasive Meningococcal Disease and Vaccines. Journal of Child. 2013;13(1):1-5. https://doi.org/10.5222/j.child.2013.001


ABNT

Hançerli Törün, S.; Salman, N. Invasive Meningococcal Disease and Vaccines. Journal of Child, [Publisher Location], v. 13, n. 1, p. 1-5, 2013.


Chicago: Author-Date Style

Hançerli Törün, Selda, and Nuran Salman. 2013. “Invasive Meningococcal Disease and Vaccines.” Journal of Child 13, no. 1: 1-5. https://doi.org/10.5222/j.child.2013.001


Chicago: Humanities Style

Hançerli Törün, Selda, and Nuran Salman. Invasive Meningococcal Disease and Vaccines.” Journal of Child 13, no. 1 (Nov. 2024): 1-5. https://doi.org/10.5222/j.child.2013.001


Harvard: Australian Style

Hançerli Törün, S & Salman, N 2013, 'Invasive Meningococcal Disease and Vaccines', Journal of Child, vol. 13, no. 1, pp. 1-5, viewed 15 Nov. 2024, https://doi.org/10.5222/j.child.2013.001


Harvard: Author-Date Style

Hançerli Törün, S. and Salman, N. (2013) ‘Invasive Meningococcal Disease and Vaccines’, Journal of Child, 13(1), pp. 1-5. https://doi.org/10.5222/j.child.2013.001 (15 Nov. 2024).


MLA

Hançerli Törün, Selda, and Nuran Salman. Invasive Meningococcal Disease and Vaccines.” Journal of Child, vol. 13, no. 1, 2013, pp. 1-5. [Database Container], https://doi.org/10.5222/j.child.2013.001


Vancouver

Hançerli Törün S, Salman N. Invasive Meningococcal Disease and Vaccines. Journal of Child [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];13(1):1-5. Available from: https://doi.org/10.5222/j.child.2013.001 doi: 10.5222/j.child.2013.001


ISNAD

Hançerli Törün, Selda - Salman, Nuran. Invasive Meningococcal Disease and Vaccines”. Journal of Child 13/1 (Nov. 2024): 1-5. https://doi.org/10.5222/j.child.2013.001



TIMELINE


First Revision01.01.2013
Last Revision05.03.2013
Published Online30.03.2013

SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.